Otsuka defends validity of injectable Abilify patent, accuses Sun Pharma of infringement
Intellectual Property 2024-05-30 2:19 pm By Sam Matthews | Melbourne
Please login to bookmark Close

Otsuka Pharmaceutical has hit back at suit filed by Indian generics company Sun Pharma seeking to invalidate its patent for blockbuster antipsychotic Abilify, filing a cross-claim seeking to restrain Sun Pharma from infringing the patent with a generic version of the drug.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au